Rg1 antibodies and uses thereof

Abstract

The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.

1 . An isolated human antibody, or antigen-binding antibody fragment thereof, or a variant thereof, that specifically binds to an epitope present in an RG1 polypeptide. 
     
     
         2 - 36 . (canceled) 
     
     
         37 . An isolated human or humanized antibody or an antigen-binding fragment thereof, which:
 (i) binds RG1 polypeptide having the amino acid sequence of SEQ ID NO:2, and   (ii) competes for the same epitope as the epitope bound by the antibody selected from the group consisting of:
 a) an isolated antibody or a fragment thereof comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 26 or SEQ ID NO: 29, or 
 b) the isolated antibody or a fragment thereof comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, or SEQ ID NO: 31 or 
 c) an isolated antibody or a fragment thereof comprising a light chain variable region having the amino acid sequence of SEQ ID NO: 26 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 27 or SEQ ID NO: 28, or 
 d) an isolated antibody or a fragment thereof comprising a light chain variable region having the amino acid sequence of SEQ ID NO: 29 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 30 or SEQ ID NO: 31. 
   
     
     
         38 . An isolated human or humanized antibody or an antigen-binding fragment thereof, which:
 (i) binds RG1 polypeptide having the amino acid sequence of SEQ ID NO:2, and   (ii) competes for the same epitope as the epitope bound by the antibody comprising:
 a) a light chain CDR3 sequence comprising the amino acid residues 110 to 117 of SEQ ID NO: 26, 
 b) a heavy chain CDR3 sequence comprising the amino acid residues 117 to 132 of SEQ ID NO: 27, 
 c) a light chain CDR1 sequence and CDR2 sequence, wherein the sequences comprise the amino acid residues 44 to 55 of SEQ ID NO: 26 and 71 to 77 of SEQ ID NO: 26, respectively, and 
 d) a heavy chain CDR1 sequence and CDR2 sequence, wherein the sequences comprise the amino acid residues 50 to 54 of SEQ ID NO: 27 and 69 to 84 of SEQ ID NO: 27, respectively. 
   
     
     
         39 . An isolated human or humanized antibody or an antigen-binding fragment thereof, which:
 (i) binds RG1 polypeptide having the amino acid sequence of SEQ ID NO:2, and   (ii) competes for the same epitope as the epitope bound by the antibody comprising:
 a) a light chain CDR3 sequence comprising the amino acid residues 110 to 117 of SEQ ID NO: 29, 
 b) a heavy chain CDR3 sequence comprising the amino acid residues 117 to 126 of SEQ ID NO: 30, 
 c) a light chain CDR1 sequence and CDR2 sequence, wherein the sequences comprise the amino acid residues 44 to 55 of SEQ ID NO: 29 and 71 to 77 of SEQ JD NO: 29, respectively, and 
 d) a heavy chain CDR1 sequence and CDR2 sequence, wherein the sequences comprise the amino acid residues 50 to 54 of SEQ ID NO: 30 and 69 to 84 of SEQ ID NO: 30, respectively. 
   
     
     
         40 . The antibody fragment of any one of  claim 37 ,  38  or  39 , wherein the antibody fragment is selected from a group of fragments consisting of Fv, F(ab′), F(ab′) 2 , scFv, minibody and diabody fragments. 
     
     
         41 . The antibody fragment of any one of  claim 37 ,  38  or  39 , wherein the antibody is a monoclonal antibody.